Autonomix announces longer-term post hoc data from PoC 1 trial

Autonomix (AMIX) Medical announced new longer-term post hoc data from its initial trial phase of its first-in-human study proof-of-concept evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. Results from the PoC 1 study demonstrated both statistically significant pain relief as early as 24-hours post-procedure and sustained pain relief lasting as far out as three to five months post-procedure, offering both immediate and lasting pain mitigation in patients with pancreatic cancer pain. Notable Longer-Term Post Hoc Analysis Findings from the PoC 1 Phase: Responding patients reported a mean 5.08 pain reduction on the VAS pain scale, or 65.6% improvement. Among responders, 100% of patients were opioid free at their 3-month post-procedure follow-up which highlights the potential for a non-opioid alternative in a highly opioid-reliant disease. Responding patients experienced remarkable improvement in global health, functional ability, and symptom management, demonstrating the procedure addresses more than just pain and has the potential to improve day-to-day living during end-stage cancer.